Variable | NEJM | Annals IM | The Lancet | The BMJ | JAMA |
---|---|---|---|---|---|
Title (%) | 9* | 95 | 97 | 100 | 98 |
Trial design | 30* | 70 | 61 | 59 | 39 |
Eligibility criteria | 57 | 77 | 83 | 84 | 78 |
Study setting | 18* | 74 | 52 | 85 | 67 |
Intervention | 78 | 88 | 92 | 88 | 87 |
Objective | 81 | 100 | 99 | 100 | 99 |
Primary outcome | 90 | 86 | 95 | 90 | 90 |
Random sequence generation | 0 | 21 | 62† | 7 | 3 |
Allocation concealment | 0 | 17 | 22 | 3 | 0 |
Blinding | 24* | 85 | 80 | 73 | 35* |
Number of randomised per group | 34* | 53 | 77 | 66 | 69 |
Number of analysed per group | 32 | 33 | 65 | 43 | 41 |
Outcome stated | 85 | 73 | 88 | 74 | 93 |
Effect size/precision | 77 | 85 | 80 | 81 | 85 |
Harms or side effects | 69† | 38 | 66 | 28 | 43 |
Interpretation stated | 98 | 100 | 100 | 98 | 100 |
Trial registration | 97 | 89 | 99 | 95 | 97 |
Source of funding | 98 | 76 | 94 | 3* | 2* |
Overall adherence | 55 | 70 | 78 | 65 | 63 |
*Journals lagged the majority by 25% or more (p<0.001) for the category.
†Journals led the majority by 25% or more (p<0.001) for the category.